78 results match your criteria Interstitial Laser Coagulation of the Prostate


Usage of GreenLight HPS 180-W laser vaporisation for treatment of benign prostatic hyperplasia.

Acta Chir Iugosl 2014 ;61(1):57-61

Introduction: Laser therapy has gained increasing acceptance as a relatively less invasive treatment for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). From the early procedure of interstitial laser coagulation through to the use of holmium laser enucleation of the prostate, there has been an expanding body of evidence on the efficacy of such procedures. One of the newer lasers is the Green Light HPS 180 W laser. Read More

View Article and Full-Text PDF
October 2015

Combination of channel-TURP and ILC versus standard TURP or ILC for elderly with benign prostatic hyperplasia: a randomized prospective trial.

Urol Int 2011 30;87(4):392-9. Epub 2011 Sep 30.

Department of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.

Purpose: A prospective randomized controlled trial was performed in elderly patients with benign prostatic hyperplasia (BPH) to evaluate the clinical effectiveness of channel transurethral resection of the prostate (C-TURP) combined with an interstitial laser coagulation (ILC) technique during a 4-year follow-up period.

Methods: A total of 150 consecutive BPH patients were randomized to an ILC+C-TURP group (n = 50), an ILC group (n = 50) and a TURP group (n = 50). Urinary tract infection, acute urinary retention and retrograde ejaculation were monitored, and the retreatment rate, international prostate symptom score (IPSS) and maximum flow rate (Q(max)) were measured. Read More

View Article and Full-Text PDF

Laser vaporization of the prostate in vivo: Experience with the 150-W 980-nm diode laser in living canines.

Lasers Surg Med 2010 Oct;42(8):736-42

Department of Urology, University Hospital Basel, Basel, Switzerland.

Background And Objective: Anatomic, tissue ablation and coagulation, and histopathologic outcomes of the 150-W 980-nm diode laser selective light vaporization (SLV™) of the prostate in the first survival study of living canines were analyzed.

Study Design/materials And Methods: Ten dogs underwent anterograde SLV™ with the 150-W 980-nm laser delivered by its side-firing fiber (Fusion™). Postoperatively, two dogs were euthanized at 3 hours as planned, six at 2-7 days due to complications, and two, without complications, at 8 weeks as planned. Read More

View Article and Full-Text PDF
October 2010

The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review.

Asian J Androl 2010 Jul 17;12(4):500-8. Epub 2010 May 17.

Division of Urology, University of Texas Medical School at Houston, Houston, TX 77030, USA.

A systematic review of randomized controlled trials and cohort studies was conducted to evaluate data for the effects of minimally invasive procedures for treatment of symptomatic benign prostatic hyperplasia (BPH) on male sexual function. The studies searched were trials that enrolled men with symptomatic BPH who were treated with laser surgeries, transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA), transurethral ethanol ablation of the prostate (TEAP) and high-intensity frequency ultrasound (HIFU), in comparison with traditional transurethral resection of the prostate (TURP) or sham operations. A total of 72 studies were identified, of which 33 met the inclusion criteria. Read More

View Article and Full-Text PDF

Laser treatments of the prostate vs TURP/ open prostatectomy: systematic review of urodynamic data.

Minerva Urol Nefrol 2009 Sep;61(3):309-24

Department of Urology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.

Unlabelled: Bladder outlet obstruction (BOO) is believed to be the major component of benign prostatic hyperplasia (BPH) that harms the urinary tract. Therefore, BOO relief is the primary treatment objective in patients with obstructive BPH. This systematic review aims to analyze urodynamic data of laser treatment modalities of the prostate in direct comparison with standard treatment (TURP or open prostatectomy). Read More

View Article and Full-Text PDF
September 2009

[Surgical and instrumental management of benign prostatic hyperplasia].

Authors:
R Muschter O Reich

Urologe A 2008 Feb;47(2):155-65

Klinik für Urologie und Kinderurologie, Diakoniekrankenhaus Rotenburg/W., Akad. Lehrkrankenhaus der Universität Göttingen, 27356, Rotenburg.

In recent decades, several various interventional procedures for the treatment of symptomatic benign prostatic hyperplasia (BPH) have been developed. Most of them were considered potential alternatives to prostatic surgery such as open prostatectomy, transurethral resection of the prostate (TURP), or transurethral incision of the prostate (TUIP). Despite good results observed in the initial clinical studies, most concepts and procedures were never generally accepted. Read More

View Article and Full-Text PDF
February 2008

New laser treatment approaches for benign prostatic hyperplasia.

Curr Urol Rep 2007 Jan;8(1):47-52

Department of Physics and Optical Science, University of North Carolina at Charlotte, 9201 University City Boulevard, Charlotte, NC 28223-0001, USA.

The recent introduction of higher power 100 W holmium:yttrium-aluminum-garnet (Ho:YAG) and 80 W potassium titanyl phosphate lasers for rapid incision and vaporization of the prostate has resulted in renewed interest in the use of lasers for treatment of benign prostatic hyperplasia (BPH). Although long-term studies are still lacking, short-term results demonstrate that these procedures are at least as safe and effective in relieving BPH symptoms as transurethral resection of the prostate and may provide reduced morbidity. Other laser techniques, such as interstitial laser coagulation and contact laser vaporization of the prostate, have lost popularity due to complications with increased catheterization time, irritative symptoms, and infection rates. Read More

View Article and Full-Text PDF
January 2007

Local anesthesia during interstitial laser coagulation of the prostate.

Authors:
Kalish R Kedia

Rev Urol 2005 ;7 Suppl 9:S23-8

Cleveland Urology Associates, Middleburg Heights, OH.

With the emergence of minimally invasive therapies for the management of symptoms of benign prostatic hyperplasia (BPH), as well as the reality of a changing medical economic environment, there is a need for a reliable local anesthesia protocol. The protocol described here for prostate anesthetic block is a safe, economical, and effective way to perform interstitial laser coagulation and other minor endoscopic urologic procedures in the office setting. Most patients experience little discomfort and recover quickly, with prompt return to normal activities. Read More

View Article and Full-Text PDF

A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.

J Urol 2006 Oct;176(4 Pt 1):1500-6

Department of Urology, Case School of Medicine, University Hospitals of Cleveland, Cleveland, Ohio 44106, USA.

Purpose: We critically evaluated the clinical outcomes and cost characteristics of alternative procedural treatment options for symptomatic benign prostatic hyperplasia.

Materials And Methods: An outcomes and cost analysis was performed for benign prostatic hyperplasia treatments, including photoselective vaporization, microwave thermotherapy, transurethral needle ablation, interstitial laser coagulation and transurethral resection. Clinical outcomes were measured by the percent improvement in American Urological Association/International Prostate Symptom Score, the maximum uroflowmetry rate and quality of life score. Read More

View Article and Full-Text PDF
October 2006

Current role of lasers in the treatment of benign prostatic hyperplasia (BPH).

Authors:
Rainer M Kuntz

Eur Urol 2006 Jun 31;49(6):961-9. Epub 2006 Mar 31.

Department of Urology, Auguste-Viktoria-Hospital, Berlin, Germany.

Objective: Evaluate the current role of lasers in the treatment of benign prostatic hyperplasia (BPH).

Methods: The results of a MEDLINE search for randomised trials and case series of the last 5 yr and published review articles were analysed for the safety and efficacy of neodymium:yttrium aluminum garnet (Nd:YAG), potassium-titanyl-phosphate (KTP), and holmium (Ho):YAG laser prostatectomy. The analysis includes 12 reports on randomised clinical trials, 2 comparative studies, 10 review articles, and a total of >5000 patients. Read More

View Article and Full-Text PDF

Techniques and long-term results of surgical procedures for BPH.

Eur Urol 2006 Jun 6;49(6):970-8; discussion 978. Epub 2006 Feb 6.

Department of Urology, University-Hospital Munich Grosshadern, Ludwig-Maximilians-University, Germany.

Objective: To provide an overview on the current status of the long-term outcomes of instrumental treatment options for patients with lower urinary tract symptoms that are suggestive of bladder outlet obstruction.

Methods: Based on MEDLINE database searches, we performed a systematic review of the literature with a focus on peer-reviewed articles about surgical benign prostatic hyperplasia (BPH) therapy published between 2000 and 2005. Special emphasis was given to randomized controlled trials on long-term outcome with a minimum follow-up of five years. Read More

View Article and Full-Text PDF

Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.

Authors:

Ont Health Technol Assess Ser 2006 1;6(17):1-121. Epub 2006 Aug 1.

Objective: The Ontario Health Technology Advisory Committee asked the Medical Advisory Secretariat (MAS) to conduct a health technology assessment on energy delivery systems for the treatment of benign prostatic hyperplasia (BPH).

Clinical Need: TARGET POPULATION AND CONDITION BPH is a noncancerous enlargement of the prostate gland and the most common benign tumour in aging men. (1) It is the most common cause of lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) and is an important cause of diminished quality of life among aging men. Read More

View Article and Full-Text PDF
October 2012

Prospective evaluation of interstitial laser coagulation of the prostate: importance of surgical technique and patient selection.

J Endourol 2005 Oct;19(8):1012-5

Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

Purpose: To evaluate the impact of improvements in surgical technique and patient selection on overall outcomes of interstitial laser coagulation (ILC) of the prostate and to describe our treatment algorithm.

Patients And Methods: During a 4-year period, 66 men with bothersome lower urinary-tract symptoms underwent ILC of the prostate using the Indigo 830e Diode Laser System (Ethicon Endo-Surgery). Patients were assessed preoperatively and followed prospectively. Read More

View Article and Full-Text PDF
October 2005

[Transurethral resection for prostatic adenoma larger than 100 ml--preoperative treatment with interstitial laser coagulation of the prostate plus chlormadinone acetate as a treatment maneuver for safer operations].

Hinyokika Kiyo 2005 Mar;51(3):159-64

Department of Urology, Furuya Hospital.

Between August 1985 and March 2004, we performed transurethral resection of the prostate (TURP) in 18 patients with benign prostatic hyperplasia (BPH) whose prostatic volume was larger than 100 ml. We divided the patients into two groups. Group A consisted of a total of 14 cases: 10 cases whose mean prostate volume was 114 ml (100 to 137 ml) and 4 cases whose prostate volume was not measured before TURP but whose mean resected prostatic tissue weight was 113 g (105 to 118 g). Read More

View Article and Full-Text PDF

Human prostatic tissue constituents respond differently to thermal injury induced by Nd-YAG laser ITT fiber applied ex-situ.

Rom J Morphol Embryol 1998 Jan-Dec;44(1-4):83-91

Department of Pathology, Hasharon Hospital, Petach-Tiqva, Israel.

Background And Objective: The human prostate is a glandular organ that has intervening fibromuscular elements. The objective of this study was to evaluate the thermocoagulative effect on the different components of the organ exposed to Nd-YAG laser irradiation using a new ITT optic fiber design (Interstitial Thermal Therapy).

Study Design/patients And Methods: Twelve fresh transvesical prostatectomy specimens were irradiated ex-situ at 4 to 6 sites using an ITT fiber with laser energies ranging from 900 to 4500 joules (J) applied at times ranging from 60 to 300 seconds corresponding to 10 to 15 watts. Read More

View Article and Full-Text PDF

Lasers in the treatment of benign prostatic hyperplasia: an update.

Curr Opin Urol 2005 Jan;15(1):55-8

Department of Urology, Royal Perth Hospital, Perth, Australia.

Purpose Of Review: Few of the original laser-based procedures from the early 1990s have withstood the test of time while some, such as holmium laser prostatectomy, have been significantly modified. New additions to the fold, such as the high-powered potassium-titanyl-phosphate (KTP) laser, use old techniques and disposables but a higher level of energy than previously. In the 12 months since September 2003, a number of important articles have appeared concerning laser prostatectomy, the subject of this review. Read More

View Article and Full-Text PDF
January 2005

Update of the minimally invasive therapies for benign prostatic hyperplasia.

Curr Opin Urol 2005 Jan;15(1):49-53

Department of Urology, University Vita-Salute-San Raffaele, San Raffaele Hospital, Milan, Italy.

Purpose Of Review: The elevated impact benign prostatic hyperplasia has on patient quality of life has determined continuous research into the development of minimally invasive therapies aimed at restoring or preserving a good quality of life. The purpose of this review is to highlight recent developments in the field of minimally invasive treatment of benign prostatic hyperplasia, and to determine their possible impact on everyday clinical practice.

Recent Findings: Recent publications have described some interesting new therapies and provided data concerning long-term follow up and cost-effectiveness that have been lacking up until now. Read More

View Article and Full-Text PDF
January 2005

Intermittent catheterization time required after interstitial laser coagulation of the prostate.

Urology 2004 Jul;64(1):79-83

Department of Urology, Hamamatsu Rosai Hospital, Shizuoka, Japan.

Objectives: To evaluate and minimize the duration of clean intermittent catheterization (CIC) required after interstitial laser coagulation of the prostate in patients with benign prostatic hyperplasia.

Methods: Patients who did not show sufficient improvement in lower urinary tract symptoms or voiding dysfunctions with alpha-1 adrenergic blockers, and who agreed to undergo interstitial laser coagulation of the prostate, were enrolled in this study. Postoperatively, the indwelling Foley catheters were removed by the next morning. Read More

View Article and Full-Text PDF

Transurethral resection versus minimally invasive treatments of benign prostatic hyperplasia: results of treatments. Our experience.

Arch Ital Urol Androl 2004 Mar;76(1):11-8

Institute of Urology, Polytechnic University of the Marche Region, Medical School, Ancona, Italy.

Objective: In this non-randomized prospective study the results of standard TURP (Transurethral Resection of the Prostate) versus other minimally invasive treatments were compared.

Materials And Methods: Among all the patients treated at our Institution for bladder outlet obstruction due to BPH (Benign Prostatic Hyperplasia) from January 1995 to June 1998, 212 patients have been evaluated; 90 patients underwent to TURP, 13 patients to TVP (Transurethral ElectroVaporization), 24 patients to TUNA (TransUrethral Needle Ablation), 71 patients to ILC (Interstitial Laser Coagulation), and 13 patients to WIT (Water-Induced Thermotherapy).

Results: TURP achieves the highest decrease of prostate volume (48. Read More

View Article and Full-Text PDF

Laser prostatectomy for benign prostatic obstruction.

Cochrane Database Syst Rev 2004 (1):CD001987

General Internal Medicine 111GIM, New Mexico VA Health Care System, 1501 San Pedro Drive SE, Albuquerque, New Mexico 87108, USA.

Background: Symptomatic benign prostatic obstruction is a common problem for older men. The gold standard treatment, transurethral resection of the prostate (TURP), significantly improves urinary symptoms and urinary flow. However, TURP has up to a 20% morbidity. Read More

View Article and Full-Text PDF

Interstitial laser photocoagulation for treatment of benign prostatic hypertrophy: outcomes and cost effectiveness.

Chang Gung Med J 2003 Nov;26(11):799-806

Department of Urology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan, ROC.

Background: We examined the efficiency and cost effectiveness of a temperature feedback diode-laser system in the treatment of benign prostatic hypertrophy (BPH).

Methods: One hundred twenty patients with symptomatic BPH were included in this study between October 1997 and January 1998. Sixty of them were treated by transurethral resection of the prostate (TUR-P), and 60 patients were treated by temperature feedback interstitial laser coagulation (ILC). Read More

View Article and Full-Text PDF
November 2003

Interstitial laser coagulation versus transurethral resection of the prostate for benign prostatic enlargement--a prospective randomized study.

Scand J Urol Nephrol 2003 ;37(6):494-7

Department of Urology, Lund University Hospital, Sweden.

Objective: Interstitial laser coagulation (ILC) of the prostate is a minimally invasive method for treating symptomatic benign prostatic enlargement (BPE). We performed a prospective randomized study to compare the clinical outcomes of ILC and transurethral resection of the prostate (TURP).

Material And Methods: Between December 1997 and February 2000, 38 patients with moderate-to-severe symptomatic BPE were included in the study. Read More

View Article and Full-Text PDF

Interstitial laser coagulation treatment of benign prostatic hyperplasia: is it to be recommended?

J Endourol 2003 Oct;17(8):595-600

Department of Urology, University Medical Center St. Radboud, Nijmegen, The Netherlands.

Purpose: To update the clinical data on the treatment of benign prostatic hyperplasia (BPH) by interstitial laser coagulation (ILC).

Material And Methods: In addition to recent review articles, original papers published during the last 2 years were surveyed. The focus was on prospective, particularly randomized, trials and on those with long-term follow-up. Read More

View Article and Full-Text PDF
October 2003

[Long-term follow-up of interstitial laser coagulation in the treatment of benign prostatic hyperplasia].

Aktuelle Urol 2003 Jan;34(1):48-51

Urologische Klinik. Klinikum Mannheim gGmbH, Universitätsklinikum, Mannheim.

Introduction: Besides standard open or transurethreal adenoma resection, less morbid interstitial laser coagulation (ILC) is an alternative therapeutical option that could reduce lower urinary tract symptoms, especially in high-risk patients. Although short-term results indicate effectiveness, reliable long-term statistics are still lacking. Therefore, to assess long-term satisfaction and overall success rate, we re-evaluated patients with a mean follow-up of 7 years after laser treatment. Read More

View Article and Full-Text PDF
January 2003

Interstitial laser coagulation of the prostate for management of acute urinary retention.

J Urol 2003 Sep;170(3):879-82

Department of Urology, Hamamatsu Rosai Hospital, Hamamatsu, Japan.

Purpose: We evaluated the clinical efficacy and benefit of interstitial laser coagulation of the prostate (ILCP) in patients with benign prostatic hyperplasia (BPH) presenting with acute urinary retention.

Materials And Methods: Patients presenting with acute urinary retention were prospectively evaluated. Patients underwent ILCP and outcomes were evaluated by post-void residual urine, maximum flow rate, International Prostate Symptom Score, and disease specific quality of life score at baseline, 1, 3, 6 and 12 months. Read More

View Article and Full-Text PDF
September 2003

Combination of interstitial laser coagulation and transurethral resection of the prostate: ex vivo evaluations.

Urology 2003 Jun;61(6):1172-6

Department of Urology, Ludwig-Maximilians-University, Munich, Germany.

Objectives: To evaluate the combination of interstitial laser coagulation (ILC) and transurethral resection of the prostate (TURP) in an ex vivo model. Perioperative bleeding is still regarded as the main complication of conventional TURP. The minimally invasive procedure ILC and the highly effective TURP seem to be a promising concept to improve hemostasis. Read More

View Article and Full-Text PDF

[Prevalence and preference with regard to various surgical treatments for benign prostatic hypertrophy: a survey for the Japanese endourology and ESWL society member].

Nihon Hinyokika Gakkai Zasshi 2003 May;94(4):495-502

Department of Urology, Graduate School of Medical Sciences, Kyushu University.

Background And Purpose: We conducted a questionnaire survey concerning the prevalence and preference with regard to various types of surgical treatment for benign prostatic hypertrophy (BPH), in order to gather preliminary data that may be helpful for standardizing the surgical treatment of BPH.

Method: A questionnaire survey was mailed to institutes in which a council member of the Japanese Endourology and ESWL Society was present. The questions dealt with the type and volume of surgical treatment experienced previously, and the treatments which had been performed in each institute during 2000. Read More

View Article and Full-Text PDF

[Interstitial laser coagulation for benign prostatic hyperplasia: clinical results of the Indigo diode laser system].

Hinyokika Kiyo 2003 Apr;49(4):195-200

Department of Urology, Kurashiki Central Hospital.

We report our experience with interstitial laser coagulation of the prostate (ILCP) using an Indigo 830j diode laser system for benign prostatic hyperplasia (BPH). From March 1998 to November 2000, we treated 45 patients between 51 and 95 years old (average 71.5) with symptomatic BPH. Read More

View Article and Full-Text PDF

Interstitial laser coagulation of the prostate: minimally invasive therapy for benign prostatic hyperplasia.

Authors:
J C Williams

Surg Technol Int 1998 ;7:317-20

Division of Urologic Surgery, University of Pittsburgh, Pa., Valley Urological Associates, Sewickley, Pa.

The morbidity and mortality associated with transurethral resection of the prostate (TURP), as therapy for benign prostatic hyperplasia (BPH), is the impetus for the urological community's search for alternative medical and surgical treatments for BPH. Interstitial Laser Coagulation of the Prostate (ILC) is a minimally invasive procedure usually performed to relieve symptomatic BPH, that is accomplished by directing laser energy into the gland via an implanted optical fiber using standard cystoscopic techniques. Treatment of adenomatous tissue with ILC reduces the size of the prostate and disrupts alpha-adrenergic nerve fibers. Read More

View Article and Full-Text PDF
October 2012